Shanton Pharma, a clinical-stage biotech company developing a novel treatment for gout, today announced topline data of a ...

dose-ranging clinical study in refractory gout patients with or without tophi, to evaluate the efficacy and safety of a 10, 30, or 60 mg tablet dose of SAP-001. The study enrolled 87 patients from ...

2,3 Shanton's Phase 2b study is a six-month, multi-center, randomized, double-blind, placebo-controlled, dose-ranging clinical study in refractory gout patients with or without tophi, to evaluate the ...

SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in uncontrolled gout SINGAPORE and PRINCETON, N.J., March 28, 2025 /PRNewswire/ -- Shanton Pharma ...

Crawling into bed to rest her painful left toe, Mel Gardener winced as she covered herself with a cotton sheet. Even the touch of this light fabric was excruciating.